In a report released today, Dev Weerasuriya from Berenberg Bank maintained a Buy rating on Teladoc (TDOC – Research Report), with a price target of $42.00. The company’s shares closed last Wednesday at $30.96, close to its 52-week low of $27.38.
According to TipRanks.com, Weerasuriya ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -20.1% and a 21.4% success rate. Weerasuriya covers the Technology sector, focusing on stocks such as Health Catalyst, Accolade, and Omnicell.
Teladoc has an analyst consensus of Moderate Buy, with a price target consensus of $47.80.
Based on Teladoc’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $565 million and GAAP net loss of $6.67 billion. In comparison, last year the company earned revenue of $454 million and had a GAAP net loss of $200 million.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TDOC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Teladoc Health, Inc. is a multinational telemedicine and virtual healthcare company. The company provides telehealth solutions, expert medical services, medical opinions, artificial intelligence and analytics, behavioral health solutions, guidance and support, and platform and program services.
Read More on TDOC: